1. hERG (KCNH2 or Kv11.1) K+ channels: screening for cardiac arrhythmia risk;Bowlby;Curr. Drug Metab.,2008
2. Guidance for industry, S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals;U.S. Food and Drug Administration,2005
3. Predictive in silico modeling for hERG channel blockers;Aronov;Drug Discov. Today,2005
4. Recent developments in computational prediction of hERG blockage;Wang;Curr. Top. Med. Chem.,2013
5. In silico models to predict QT prolongation;Aronov,2007